世界の鉄欠乏症注射剤市場の概要と2031年までの予測 - 市場分析と市場シェア

世界の鉄欠乏症注射剤市場 - 業界概要

鉄欠乏症は、体内の鉄分が不足してヘモグロビンを生成できなくなることで起こり、鉄欠乏性貧血につながります。症状には、疲労、衰弱、皮膚の蒼白、息切れ、めまいなどがあります。鉄欠乏症の注射剤市場は、特に経口鉄剤の入手が限られている地域での貧血症例の増加により、世界的な急成長を遂げています。世界保健機関 (WHO) によると、貧血は人口の 24.8% に相当する 16 億 2000 万人に影響を及ぼしています。世界中で、注射剤鉄などの効果的で迅速な治療オプションの需要が高まっています。

Data Bridge Market Research の市場レポートでは、最近の新しい開発、市場シェア、セグメンテーションと地域分析に基づく市場動向、市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的な市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。市場に関する詳細情報を入手するには、Data Bridge Market Research の専門アナリスト チームにお問い合わせください。当社のチームは、情報に基づいた市場決定を行い、ビジネスの成長を達成できるようお手伝いします。

世界の鉄欠乏症注射剤市場規模

With advancements in injectable iron formulations, such as ferric carboxymaltose and iron isomaltoside, the Iron Deficiency Injectable is experiencing increased acceptance due to enhanced safety profiles, higher bioavailability, and simplicity of administration. Such variables, together with rising healthcare expenditure and higher awareness of anemia's health consequences, are likely to drive Global Iron Deficiency Injectable Market growth. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Iron Deficiency Injectable Market is increasing at a CAGR of 9.20%. Our detailed analysis forecasts that the market is valued at USD 12.14 billion in 2023 and is expected to grow upto USD 24.55 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Iron Deficiency Injectable Market Dynamics

Global Iron Deficiency Injectable Market Growth Drivers

Prevalence of PCOS

According to the World Health Organization (WHO), PCOS affects an estimated 8–13% of women of reproductive age, translating to between 5% and 10% of women aged 15 to 44. Women with PCOS are more likely to develop iron deficiency anemia due to irregular menstrual cycles, which can cause excessive blood loss and chronic iron depletion. The growing awareness and diagnosis of PCOS, along with the rising prevalence of iron deficiency among affected women, contribute to the global iron deficiency injectable market growth.

Increasing prevalence of anemia

The increasing prevalence of anemia is a key growth factor for the worldwide iron deficiency injectable market. With anemia impacting 1.62 billion people, or 24.8% of the global population, there is an increasing demand for efficient and effective treatment alternatives. Injectable iron therapy have emerged as an important respond to, especially in areas where oral iron supplements are either unavailable, poorly tolerated, or inefficient. As awareness of anemia's widespread impact rises, healthcare practitioners are increasingly turning to injectable iron as a quick, dependable, and scalable therapy option, considerably contributing to Global Iron Deficiency Injectable market growth.

Global Iron Deficiency Injectable Market Growth Opportunities

Advancements in Injectable Iron Formulations

The introduction of newer formulations, such as ferric carboxymaltose and iron isomaltoside, have transformed treatment by providing superior safety and efficacy profiles compared to traditional oral supplements. For instance, ferric carboxymaltose enables for the administration of greater single doses of iron, up to 1,000 mg, in just 15 minutes, making it useful for patients with acute iron shortage who require immediate replenishment. Such formulations have improved patient outcomes and lowered side effects thus contributing to the Global Iron Deficiency Injectable Market growth.

Growing Pediatric and Geriatric Care Markets

Injectable iron is crucial for managing severe anemia in children who cannot benefit from oral supplements, especially in high-malnutrition regions, with tailored formulations enhancing treatment efficacy. Similarly, it offers a vital solution for elderly patients with absorption issues due to chronic conditions, improving management and quality of life. By addressing the unique needs of diverse age groups, the Global Iron Deficiency Injectable market can expand and provide effective solutions across diverse populations.

Global Iron Deficiency Injectable Market Growth Challenges

Risk of Adverse Reactions

Allergic reactions, including mild symptoms like rashes and itching to severe responses such as anaphylaxis, affect patients receiving intravenous iron. Local injection site reactions, such as discomfort, swelling, and redness, might impair patient comfort and adherence, limiting therapy acceptability. Additionally, long-term safety concerns concerning repeated injectable iron treatments include potential effects on organ systems, such as the liver, which necessitate continual monitoring to avoid iron overload and accompanying consequences. Consequently, posing a challenge for Global Iron Deficiency Injectable Market growth.

Lack of Patient Awareness

Patients often lack knowledge about the advantages of injectable iron over oral supplements, such as more rapid and effective treatment for severe anemia. For instance, injectable formulations like ferric carboxymaltose can deliver up to 1,000 mg of iron in a single dose, which is crucial for managing severe anemia where oral supplements may require extended periods to be effective. This lack of specific knowledge can lead to underutilization of injectable iron therapies, resulting in hindering Global Iron Deficiency Injectable Market growth.

Global Iron Deficiency Injectable Market Restraints

Regulatory and market approval hurdles

The complex regulatory landscapes across different regions can create significant barriers for the Global Iron Deficiency Injectable Market Growth. For instance, The Pharmaceuticals and Medical Devices Agency (PMDA) Regulations, Japan requires foreign companies to conduct additional clinical trials in Japan to verify the safety and efficacy of new injectable iron therapies within the Japanese population. These trials must adhere to Japanese Good Clinical Practice (GCP) guidelines. Such guidelines can significantly impact the timeline and cost for introducing new injectable iron therapies to these Iron Deficiency Injectable Market.

Global Iron Deficiency Injectable Market Scope and Trends

• Iron supplementation boosts RSL3-induced ferroptosis to both treat naïve prostate cancer and prevent castration-resistant prostate cancer.
• Ferric carboxymaltose (FCM), an injection utilized globally for treating iron deficiency in cancer and chronic kidney disease patients, has been shown by AIIMS doctors to be both effective and safe for pregnant women with moderate to severe anemia.
• Newer formulations, like iron isomaltoside 1000, have been shown to have fewer adverse reactions compared to older products, such as dextran-based irons, thereby broadening their use to more patients with varying health conditions.
• The Feraheme (ferumoxytol) auto-injector is designed to make at-home administration more accessible and less painful for patients.

Global Iron Deficiency Injectable Market Regional Analysis – Market Trends

Key Insights

• The U.S. and Canada are leading markets for iron deficiency injectables, driven by advanced healthcare systems and high iron deficiency rates. The U.S., in particular, sees significant use of products like ferric carboxymaltose and iron isomaltoside due to their effectiveness and convenience in treating severe anemia.
• アジア太平洋地域では、鉄欠乏症注射剤市場が急成長を遂げており、中国やインドなどの国々の貢献が大きい。医療投資の増加と鉄欠乏性貧血の罹患率の増加が需要を牽引している。中国では、政府の医療イニシアチブと意識の高まりに支えられ、貧血に対処するための国の幅広い取り組みの一環として、注射剤鉄の使用が拡大している。
• ヨーロッパ地域では、注射による鉄剤療法の使用をサポートする確立された医療制度と規制枠組みの恩恵を受けています。たとえばドイツでは、先進的な注射剤が利用可能であり、患者ケアと治療効果に関する同国の高い基準に合致しています。

 世界の鉄欠乏症注射剤市場の主要プレーヤー

• アッヴィ社（米国）
• Covis Pharma GmbH (米国)
• 第一三共株式会社（日本）
• フレゼニウス カビ AG (ドイツ)
• Vifor Pharma Management Ltd.（スイス）
• PHARMACOSMOS A/S（デンマーク）
• シールド・セラピューティクス（英国）
• アメリカン・リージェント社（米国）
• ロックウェルメディカル社（米国）
• アポテックス株式会社（カナダ）
• バイエルAG（ドイツ）
• アケビア・セラピューティクス社（米国）
• GSK plc（英国）
• ノバルティスAG（スイス）
• アエトナ社（米国）
• ファイザー社（米国）
• シスタケア レメディーズ (インド)
• BSAファーマ株式会社（インド）

世界の鉄欠乏症注射剤市場の最近の動向

• 2024 年 3 月、Cadila Pharmaceuticals は貧血治療用の鉄注射剤を発売します。Redshot 注射剤は、耐容性が高く、アレルギーのリスクがほとんどない静脈内鉄剤で、この注射によりヘモグロビン レベルの改善が促進され、枯渇した鉄分が急速に補充されます。
• 2023 年 5 月、Emcure Pharmaceuticals は Orofer FCM 750 を発売し、鉄欠乏性貧血の治療薬として FCM の 750 mg 注射剤を発売するインド初の企業となります。
• 2024年5月、AIIMSデリーのインド医学研究者らは、副作用がなく安価な一回限りの静脈内（IV）鉄注射を開発した。これは、鉄欠乏症率が世界でも最も高い国の一つであるインドにとって、健康補助薬となる可能性がある。
• 2023年6月、FDAは、運動能力の向上を目的として、ニューヨーク心臓協会（NYHA）クラス2または3に分類される心不全の成人患者の鉄欠乏症の治療に、カルボキシマルトース鉄注射剤を承認しました。

SKU-57258